Carlos A. Q. Santos, Daniel C. Brennan, William C. Chapman, Victoria J. Fraser, Margaret A. Olsen – 11 February 2015 – Delayed‐onset cytomegalovirus (CMV) disease can occur among liver transplant recipients after CMV prophylaxis is stopped. We hypothesized that delayed‐onset CMV disease (>100 days after transplant) occurs more commonly than early‐onset CMV disease and is associated with clinical sepsis and death.

Kellie Young, Nicholas Fidelman, Francis Y. Yao, Nancy K. Hills, Maureen P. Kohi, K. Pallav Kolli, Andrew G. Taylor, Robert K. Kerlan – 11 February 2015 – The goal of this study was to determine whether the detection of discordant numbers of hypervascular foci at hepatic angiography versus contrast‐enhanced (CE) cross‐sectional imaging [computed tomography (CT) or magnetic resonance imaging (MRI)] is associated with adverse clinical outcomes in patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation.

Philippe Ichai, Camille Legeai, Claire Francoz, Karim Boudjema, Olivier Boillot, Christian Ducerf, Philippe Mathurin, François‐René Pruvot, Bertrand Suc, Philippe Wolf, Olivier Soubrane, Yves Patrice Le Treut, Daniel Cherqui, Laurent Hannoun, Georges‐Philippe Pageaux, Jean Gugenheim, Christian Letoublon, Jean Saric, Vincent Di Martino, Armand Abergel, Laurence Chiche, Teresa Maria Antonini, Christian Jacquelinet, Denis Castaing, Didier Samuel, the French Liver Transplant Teams – 11 February 2015 – In France, decisions regarding superurgent (SU) liver transplantation (LT) for patients with a

James L. Boyer – 11 February 2015

Thomas D. Schiano, Tyler Bourgoise, Rosamond Rhodes – 4 February 2015 – In making liver transplantation (LT) listing decisions, transplant programs accept that very large differences in expected 5‐year posttransplant survival should matter and that small differences in expected survival should not matter. To date, the transplant community has not explicitly addressed the difficult question of how to make decisions when the differences are less dramatic.

C. Matthew Hawkins, Dennis W. W. Shaw, Patrick J. Healey, Simon P. Horslen, Andre A. S. Dick, Seth Friedman, Giridhar M. Shivaram – 3 February 2015 – The objective of this study was to determine which transabdominal ultrasound parameters correlate with portal vein stenosis (PVS) on percutaneous transhepatic portal venography in pediatric liver transplant patients. A retrospective review was performed of percutaneous transhepatic portal venograms performed between 2005 and 2013. The findings were compared to those from ultrasounds performed before venography and at the baseline.

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo – 2 February 2015 – Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects.

Qing Pang, Xin Sen Xu, Jing Yao Zhang, Kai Qu, Wei Chen, Chang Liu – 2 February 2015

Vincent Montoya, Andrea D. Olmstead, Naveed Z. Janjua, Patrick Tang, Jason Grebely, Darrel Cook, P. Richard Harrigan, Mel Krajden – 2 February 2015 – The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time of diagnosis is desirable to improve the quality of surveillance information. The aim of this study was to differentiate acute from chronic HCV infections utilizing deep sequencing.

Augusto Villanueva, Anna Portela, Sergi Sayols, Carlo Battiston, Yujin Hoshida, Jesús Méndez‐González, Sandrine Imbeaud, Eric Letouzé, Virginia Hernandez‐Gea, Helena Cornella, Roser Pinyol, Manel Solé, Josep Fuster, Jessica Zucman‐Rossi, Vincenzo Mazzaferro, Manel Esteller, Josep M. Llovet, on behalf of the HEPTROMIC Consortium – 2 February 2015 – Epigenetic deregulation has emerged as a driver in human malignancies. There is no clear understanding of the epigenetic alterations in hepatocellular carcinoma (HCC) and of the potential role of DNA methylation markers as prognostic biomarkers.